Finance
Novartis raises FY 2024 guidance on strong Q1 sales and profit growth
Novartis has reported robust first-quarter results, leading the Swiss drugmaker to raise its full-year guidance for 2024. The company now anticipates net sales to grow by a high-single to low double-digit percentage, an upgrade from its previous mid-single-digit growth forecast. Adjusted operating income is also expected to see a significant